REGULAR CONTENT
Final ID
572
Type
Original Scientific Research-Oral or Pos
Authors
B Tsui1, J Zeng1, E Moon1, B Kapoor1, M Sands1, W Wang2
Institutions
1Cleveland Clinic, Cleveland, OH, 2Mayo Clinic, Jacksonville, FL
Purpose
To retrospectively investigate the safety, efficacy, and complications of Trapease inferior vena cava (IVC) filters.
Materials & Methods
All cases of patients who received a Trapease filter at a single healthcare system between April 2003 and January 2013 were identified, and outcomes were reviewed through the hospital electronic medical chart.
Results
There was a total of 594 patients (278 women; mean age, 68.9±13.6 years; range, 19.2-96.3 years) who received a Trapease filter in this study. The study duration was 88 months with median clinical follow-up of 3.6 months (range, 0-148.3 mo). During follow-up, 489 of 594 (82.3%) patients died and 105 remained alive with filters in situ. There were 9 cases of breakthrough pulmonary embolism (PE) that occurred out of 582 patients with clinical follow-up (1.5%). Among 128 patients with direct filter imaging, there were 17 cases of filter fracture (13.3%). Out of 39 available CT scans, there were 8 cases of thrombus trapped inside the filter (20.5%) including 2 cases of caval occlusion. Recurrent deep vein thrombosis occurred in 109 patients out of patients with clinical follow-up (18.7%).
Conclusions
The majority of the patients who received Trapease filters died during follow-up, which indicates the filter was primarily implanted in terminal patients with permanent indications. This study demonstrates a relatively high rate of filter fracture but no fracture fragment migration. There was a high rate of trapped thrombus in patients receiving this filter. Rates of PE breakthrough were comparable to other filters on the market.
Final ID
572
Type
Original Scientific Research-Oral or Pos
Authors
B Tsui1, J Zeng1, E Moon1, B Kapoor1, M Sands1, W Wang2
Institutions
1Cleveland Clinic, Cleveland, OH, 2Mayo Clinic, Jacksonville, FL
Purpose
To retrospectively investigate the safety, efficacy, and complications of Trapease inferior vena cava (IVC) filters.
Materials & Methods
All cases of patients who received a Trapease filter at a single healthcare system between April 2003 and January 2013 were identified, and outcomes were reviewed through the hospital electronic medical chart.
Results
There was a total of 594 patients (278 women; mean age, 68.9±13.6 years; range, 19.2-96.3 years) who received a Trapease filter in this study. The study duration was 88 months with median clinical follow-up of 3.6 months (range, 0-148.3 mo). During follow-up, 489 of 594 (82.3%) patients died and 105 remained alive with filters in situ. There were 9 cases of breakthrough pulmonary embolism (PE) that occurred out of 582 patients with clinical follow-up (1.5%). Among 128 patients with direct filter imaging, there were 17 cases of filter fracture (13.3%). Out of 39 available CT scans, there were 8 cases of thrombus trapped inside the filter (20.5%) including 2 cases of caval occlusion. Recurrent deep vein thrombosis occurred in 109 patients out of patients with clinical follow-up (18.7%).
Conclusions
The majority of the patients who received Trapease filters died during follow-up, which indicates the filter was primarily implanted in terminal patients with permanent indications. This study demonstrates a relatively high rate of filter fracture but no fracture fragment migration. There was a high rate of trapped thrombus in patients receiving this filter. Rates of PE breakthrough were comparable to other filters on the market.